Jaqueline Cristina Fernandes

• Abstract

  The populations of cells, molecules or pathways identified in CRIO as possible targets for therapy will be subjected to preclinical validation using patient-derived organoids (PDO) and xenografts (PDX) in humanized immunodeficient mice. Briefly, to generate the humanized PDX models, NSG mice will be injected with autologous human immune cells and later implanted with previously generated …

  Establishing patient-derived platform to validate putative targets for immunotherapy, BP.PD

• Abstract

  Bone marrow neoplasias are aggressive disorders with low healing potential. As the incidence of Cancer increases with age, a growing number of older individuals are receiving therapy for Cancer and frequently in intensive modalities. As these older patients tend to present comorbidities, treatment decisions can often become difficult due to their fragile physical state which may affect th…

  Predictors of severity and new treatments for Bone Marrow Neoplasias/mechanisms by which quercetin, epigallocatechin 3-gallate, gallic acid, turmeric, artemisimna and derivatives shape epigenetic alterations and energetic metabolism in the myelodysplasia, BP.PD

• Abstract

  JAK2, MPL and CALR mutations activate the JAK/STAT pathway, confer cellular proliferation independent of growth factors and contribute to the pathogenesis of Myeloproliferative Neoplasms (MPN). Ruxolitinib is a selective inhibitor for JAK1/JAK2 approved for the treatment of Primary Myelofibrosis. However, the lack of efficiency in inducing complete remission in patients with MPN indicates…

  Investigation of mutations in IGF1R/IRS pathway in Myeloproliferative Neoplasm and the effect of pharmacological inhibitors of this signaling pathway in JAK2V617F knockin murine model, BP.DR

(Only some records are available in English at this moment)